208 related articles for article (PubMed ID: 16428509)
1. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.
Jørgensen HG; Copland M; Allan EK; Jiang X; Eaves A; Eaves C; Holyoake TL
Clin Cancer Res; 2006 Jan; 12(2):626-33. PubMed ID: 16428509
[TBL] [Abstract][Full Text] [Related]
2. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
3. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
4. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
5. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Smith BD; Kasamon YL; Kowalski J; Gocke C; Murphy K; Miller CB; Garrett-Mayer E; Tsai HL; Qin L; Chia C; Biedrzycki B; Harding TC; Tu GH; Jones R; Hege K; Levitsky HI
Clin Cancer Res; 2010 Jan; 16(1):338-47. PubMed ID: 20048335
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
7. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.
Foo J; Drummond MW; Clarkson B; Holyoake T; Michor F
PLoS Comput Biol; 2009 Sep; 5(9):e1000503. PubMed ID: 19749982
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
10. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Wang Y; Cai D; Brendel C; Barett C; Erben P; Manley PW; Hochhaus A; Neubauer A; Burchert A
Blood; 2007 Mar; 109(5):2147-55. PubMed ID: 17090651
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
Holtz MS; Slovak ML; Zhang F; Sawyers CL; Forman SJ; Bhatia R
Blood; 2002 May; 99(10):3792-800. PubMed ID: 11986238
[TBL] [Abstract][Full Text] [Related]
13. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Bashir Q; De Lima MJ; McMannis JD; Garcia-Manero G; Shpall E; Kantarjian H; Cortes JE; O'Brien SM; Jones D; Qazilbash M; Wei W; Giralt SA; Champlin RE; Hosing C
Leuk Lymphoma; 2010 Aug; 51(8):1478-84. PubMed ID: 20658954
[TBL] [Abstract][Full Text] [Related]
15. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
Jamieson CH; Ailles LE; Dylla SJ; Muijtjens M; Jones C; Zehnder JL; Gotlib J; Li K; Manz MG; Keating A; Sawyers CL; Weissman IL
N Engl J Med; 2004 Aug; 351(7):657-67. PubMed ID: 15306667
[TBL] [Abstract][Full Text] [Related]
17. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP; Fang BJ; Wei XD; Zheng S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
[TBL] [Abstract][Full Text] [Related]
18. Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
Ota S; Musashi M; Kondo K; Toyoshima N; Toubai T; Onozawa M; Mori A; Hashino S; Tanaka J; Matsuno K; Imamura M; Asaka M
Acta Haematol; 2006; 116(1):8-18. PubMed ID: 16809884
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
Marley SB; Lewis JL; Schneider H; Rudd CE; Gordon MY
Br J Haematol; 2004 May; 125(4):500-11. PubMed ID: 15142121
[TBL] [Abstract][Full Text] [Related]
20. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
Graham SM; Jørgensen HG; Allan E; Pearson C; Alcorn MJ; Richmond L; Holyoake TL
Blood; 2002 Jan; 99(1):319-25. PubMed ID: 11756187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
